UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000052358 |
|---|---|
| Receipt number | R000059774 |
| Scientific Title | Effects of osteoporosis treatment for orthopaedics surgery |
| Date of disclosure of the study information | 2023/11/01 |
| Last modified on | 2024/03/26 05:13:35 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of osteoporosis treatment for orthopaedics surgery
Acronym
Effects of osteoporosis treatment for orthopaedics surgery
Scientific Title
Effects of osteoporosis treatment for orthopaedics surgery
Scientific Title:Acronym
Effects of osteoporosis treatment for orthopaedics surgery
Region
| Japan | North America |
Condition
Condition
Osteoporosis
Classification by specialty
| Endocrinology and Metabolism | Geriatrics | Orthopedics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Osteoporosis is a key therapeutic target that needs to be addressed to ensure successful orthopedic surgery. However, the efficacy of pharmacological interventions in this context remains unclear. Our study aims to compare the effects of osteoporosis treatment on orthopedic surgery using advanced biomechanical analysis.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Biomechanical parameters related to orthopedic surgery
Key secondary outcomes
Bone mineral density
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 55 | years-old | <= |
Age-upper limit
| 95 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Data will be collected retrospectively from FUJIGOKO STUDY (IRB approved: registry data for the patients who diagnose and started treatment). Key inclusion criteria; Diagnosed osteoporosis treated with romosozumab, Teriparatide or Denosumab / Have DXA, Blood test and CT scan at drug initiation and 12 months.
Key exclusion criteria
Patients with malignancies, or complications that affect bone mineral conditions are excluded.
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | Koji |
| Middle name | |
| Last name | Ishikawa |
Organization
Showa University
Division name
Department of Orthopaedic Surgery
Zip code
142-8666
Address
Building No.6, room517, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8666, Japan
TEL
0337848543
koji.ishikawa@med.showa-u.ac.jp
Public contact
Name of contact person
| 1st name | Koji |
| Middle name | |
| Last name | Ishikawa |
Organization
Showa University
Division name
Department of Orthopaedics Surgery
Zip code
142-8666
Address
Building No.6, room517, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8666, Japan
TEL
0337848543
Homepage URL
koji.ishikawa@med.showa-u.ac.jp
Sponsor or person
Institute
Showa University
Institute
Department
Personal name
Funding Source
Organization
Amgen
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Yamanashi Red Cross Hospital
Address
6663-1 Funatsu Fujikawaguchiko-machi Minamitsuru-gun,Yamanashi, 401-0301, Japan
Tel
0555-72-2222
soumuka@yamanashi-med.jrc.or.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 11 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2023 | Year | 09 | Month | 29 | Day |
Date of IRB
| 2023 | Year | 10 | Month | 01 | Day |
Anticipated trial start date
| 2023 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2024 | Year | 11 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Data will be collected retrospectively from FUJIGOKO STUDY (IRB approved: registry data for the patients who diagnose and started treatment). Key inclusion criteria; Diagnosed osteoporosis treated with romosozumab, Teriparatide or Denosumab / Have DXA, Blood test and CT scan at drug initiation and 12 months. Collected data will be analyzed using advanced biomechanical analysis.
Management information
Registered date
| 2023 | Year | 09 | Month | 30 | Day |
Last modified on
| 2024 | Year | 03 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000059774
